Bedrosian Camille L's Form 4 filing
Ultragenyx Pharmaceutical Inc. (RARE) · filed Mar 3, 2023
- Accession no.
- 0001209191-23-016053
- Filed
- Mar 3, 2023
- Trade date
- Mar 1, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $175.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bedrosian Camille LCIK 0001326969 | Officer (EVP and Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2023 | Common Stock | AGrant or awardAcquired | +2,663 | $0.00 | $0 | 50,601 | Direct | |
| Mar 1, 2023 | Common Stock | SSaleDisposed | −3,881 | $45.25 | −$175,615.25 | 46,720 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.